Notices. Notice of public meeting
1,973 words·~9 min read·
/register/2006/04/20/06-3749A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 6715-01-M FEDERAL RESERVE SYSTEM Formations of, Acquisitions by, and Mergers of Bank Holding Companies The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.* ) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.
The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843).
Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center Web site at *http://www.ffiec.gov/nic/* . Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 15, 2006. **A. Federal Reserve Bank of Richmond** (A. Linwood Gill, III, Vice President) 701 East Byrd Street, Richmond, Virginia 23261-4528: *1.
BB&T Corporation* , Winston-Salem, North Carolina; to merge with First Citizens Bancorp, Cleveland, Tennessee, and thereby indirectly acquire voting shares of The Bank/First Citizens Bank, Cleveland, Tennessee, The Home Bank, Ducktown, Tennessee, and The Home Bank of Tennessee, Maryville, Tennessee. **B. Federal Reserve Bank of St. Louis** (Glenda Wilson, Community Affairs Officer) 411 Locust Street, St. Louis, Missouri 63166-2034: *1. Triumph Bancshares, Inc.* , Germantown, Tennessee; to become a bank holding company by acquiring 100 percent of the voting shares of Triumph Bank, Germantown, Tennessee (in organization). **C.
Federal Reserve Bank of Kansas City** (Donna J. Ward, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001: *1. Dickinson Financial Corporation II* , Kansas City, Missouri; to acquire 100 percent of the voting shares of Southern Commerce Bank, Tampa, Florida. Board of Governors of the Federal Reserve System, April 17, 2006. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. E6-5930 Filed 4-19-06; 8:45 am] BILLING CODE 6210-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel:
Establishing a Surveillance System for Chronic Kidney Disease in the U.S., Program Announcement PEP 2006-R-08 *Correction:* This notice was published in the **Federal Register** on April 10, 2006, Volume 71, Number 68, page 18102. The matters to be discussed during the Special Emphasis Panel meeting have been changed. *Matters to be Discussed:* To conduct an expert review of the scientific and technical merit of research proposals in response to the development of a comprehensive national kidney disease surveillance system that will capture and track all manifestations of Chronic Kidney Disease in the general population.
FOR FURTHER INFORMATION CONTACT: Felix Rogers, PhD, M.P.H., Scientific Review Administrator, CDC, 1600 Clifton Road, NE., Mailstop E-05, Atlanta, GA 30333, Telephone Number 404.639.6101, e-mail *fxr3@cdc.gov* . The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.
Dated: April 14, 2006. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E6-5928 Filed 4-19-06; 8:45 am] BILLING CODE 4163-18-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Exotic Animal Importation, Sale, and Distribution Discussions; Notice of Public Meeting AGENCY: Centers for Disease Control and Prevention, Department of Health and Human Services. ACTION: Notice of public meeting.
SUMMARY: This notice announces a public meeting on the subject of the importation, sale, and distribution of exotic animals. The purpose of the meeting is to gather information and discuss issues and concerns related to infectious disease threats associated with the importation, sale, and distribution of exotic animals. DATES: The public meeting will be held May 18, 2006, from 1 p.m. to 5 p.m. in Decatur, Georgia. Registration will begin at 12 p.m. ADDRESSES: The public meeting will be held at the following location:
Holiday Inn Decatur Conference Plaza, 130 Clairemont Ave., Decatur, GA 30030. Persons who are unable to attend the meeting may e-mail, fax, or mail their comments to: Attn: Kelly Crossett, *kcrossett@constellagroup.com;* fax 919-544-7507; Constella Group LLC, 2605 Meridian Parkway, Durham, NC 27713; Written comments regarding the subject of this meeting that are received by May 18, 2006 will receive the same consideration as statements made at the public meeting. FOR FURTHER INFORMATION CONTACT:
Attn: Kelly Crossett, telephone 919-313-7615; *kcrossett@constellagroup.com;* fax 919-544-7507; Constella Group LLC, 2605 Meridian Parkway, Durham, NC 27713. SUPPLEMENTARY INFORMATION: Participation at the Public Meeting Submit requests to present a statement at the public meeting to the contact listed in the section titled FOR FURTHER INFORMATION CONTACT . The CDC should receive your requests to present oral statements at the public meeting no later than 10 days prior to the meeting.
Include a written summary of oral remarks you would like to present and the estimated time needed for your presentation. A maximum of 15 minutes per speaker will be permitted. Requests received after the date specified above will be scheduled during the meeting if time allows; however, the names of those individuals may not appear on the written agenda. The CDC will prepare an agenda of speakers available at the meeting. To accommodate as many speakers as possible, the amount of time allocated to each speaker may be less than the estimated 15 minute maximum.
Those persons desiring to have audiovisual equipment available should notify the CDC when they request placement on the agenda. All statements submitted during the meeting will be considered part of the public record. Background Zoonoses are diseases that can be transmitted from animals to people, and prevention of zoonoses in humans poses special challenges and requires consideration of the role of exotic animals in disease transmission. Wild exotic animals may carry a variety of known and emerging zoonotic pathogens.
The 2003 outbreak of monkeypox in the United States, which involved 37 confirmed human cases, ultimately traced back to the importation of African rodents, and illustrates the special risk associated with keeping wild animals as pets. CDC's regulations regarding the importation of African rodents may be found at 42 CFR 71.56. In addition, CDC has issued orders prohibiting the introduction into the United States of birds from countries where highly pathogenic avian influenza H5N1 subtype is present and civets.
These actions were taken to prevent the introduction of monkeypox, avian influenza, and SARS-coronavirus into the United States. However, these actions may not fully protect the general public against the entry of zoonotic diseases because they are limited to specific species. The American Veterinary Medical Association (AVMA), the Council of State and Territorial Epidemiologists (CSTE), and the National Association of State Public Health Veterinarians (NASPHV) have issued position statements calling for CDC to coordinate a meeting to address the issue of infectious disease risks associated with the importation of exotic animals.
This meeting will invite discussion from several federal agencies with regulatory oversight of animals, interested stakeholders (including AVMA, CSTE, and NASPHV), and the general public regarding infectious disease threats related to exotic animal importation, sale, and distribution. The public meeting will be used as a forum to share information, answer questions, and discuss potential solutions concerning infectious disease risks associated with exotic animal importation, sale, and distribution.
Public Meeting Procedures The following procedures for this meeting are as follows: 1. Admission and participation in the public meeting are free. The meeting will be open to all persons who have requested in advance to present statements or who register on the day of the meeting (between 12 p.m. and 1 p.m.). 2. Representatives from the CDC will conduct the public meeting. A panel of Federal personnel and representatives from veterinary and public health organizations will discuss information presented by participants. 3.
The public meeting is intended as a forum to share information and answer questions concerning infectious disease risks associated with the importation, sale, and distribution of exotic animals. Participants must limit their presentations to the issue of exotic animal importation, sale, and distribution. 4. All interested parties will have the opportunity to present any information on the topic they want to be available to CDC and other Federal partners. The CDC and other federal partners will then have the opportunity to explain the methodology and technical assumptions supporting its current observations. 5.
Federal staff, representatives from public health and veterinary organizations, and public participants may engage in a full discussion of all technical material presented at the meeting. Anyone presenting conclusions will be expected to submit their supporting data to the CDC. 6. The CDC will try to accommodate all speakers. A maximum of 15 minutes will be allow ed for each speaker. Time may be additionally limited for each presentation, depending on the number of speakers. 7.
Sign interpretations will be made available at the meeting, including assistive listening devices, if requested 15 calendar days before the meeting. 8. Proceedings of the meeting will be recorded and a summary will be posted in the **Federal Register** . 9. The CDC will review and consider all material presented by participants at the public meeting. Position papers or material presenting views or information related to the subject of the meeting may be accepted. The CDC requests that persons participating in the meeting provide 10 copies of all materials to be presented for distribution to the panel members; other copies may be provided to the audience at the discretion of the participant. 10.
Statements made by CDC personnel and other federal personnel are intended to facilitate discussion of the issues or to clarify issues. Such statements should not be interpreted as providing legal, professional, or other advice. 11. The meeting is designed to share information and solicit individual views from the public and additional information. The meeting will not operate in consensus fashion. The meeting will be conducted in an informal and non-adversarial manner. All statements submitted during the meeting will be considered part of the public record.
Dated: April 12, 2006. James D. Seligman, Chief Information Officer, Centers for Disease Control and Prevention. [FR Doc. E6-5926 Filed 4-19-06; 8:45 am] BILLING CODE 4163-18-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Statement of Organization, Functions, and Delegations of Authority Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 71 FR 6777, dated February 9, 2006) is amended to reflect the title change for the Division of Policy Analysis and Coordination, Office of Enterprise Communication, Office of the Director, Centers for Disease Control and Prevention.
Section C-B, Organization and Functions, is hereby amended as follows: Delete in its entirety the title for the *Division of Policy Analysis and Coordination (CAUB)* and insert the *Division of Issues Management and Executive Secretariat (CAUB).* Dated: April 4, 2006. William H. Gimson, Chief Operating Officer, Centers for Disease Control and Prevention (CDC). [FR Doc. 06-3749 Filed 4-19-06; 8:45 am]
Connectionstraces to 3
Traces to 3 documents
2 references not yet in our index
- 12 CFR 225
- 42 CFR 71.56
Citation graph
cites case law
Cites 5Cited by 0 across 0 sources